3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
10
Breast Neoplasms
9
Prostatic Neoplasms
7
Multiple Myeloma
6
Colorectal Neoplasms
5
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Leukemia, Myeloid, Acute
4
Head and Neck Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Recurrence
3
Neoplasms, Plasma Cell
3
Lung Neoplasms
3
Hematologic Neoplasms
3
Glioblastoma
3
Carcinoma, Ovarian Epithelial
3
Urinary Bladder Neoplasms
2
Neoplasms by Site
2
Mycoses
2
Medication Adherence
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Follicular
2
Leukemia
2
Carcinoma, Transitional Cell
2
COVID-19
2
Adenocarcinoma
2
Uveal Melanoma
1
Urologic Neoplasms
1
Urologic Diseases
1
Urogenital Neoplasms
1
Interventions
telapristone acetate
18
vilaprisan
12
relugolix
11
estradiol, norethindrone drug combination
9
asoprisnil
9
Estradiol
8
elagolix
7
Uterine Myomectomy
7
ulipristal acetate
6
Norethindrone Acetate
6
Leuprolide
5
linzagolix
4
Uterine Artery Embolization
3
Sugars
3
ulipristal
2
Progestins
2
Mifepristone
2
epigallocatechin gallate
1
carbetocin
1
Vitamin D
1
Vitamin B 6
1
Therapeutics
1
Standard of Care
1
Sodium Chloride
1
Robotic Surgical Procedures
1
Radiofrequency Ablation
1
Progesterone
1
Microbial Collagenase
1
Megestrol Acetate
1
Medroxyprogesterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Leiomyoma
×
Standard of Care
×
Clear all
NCT03194646
2025-07-28
ASTEROID 6
Bayer
Phase 3
Terminated
1,272 enrolled
16 charts